Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Millen

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cephalalgia : an International Journal of Headache|June 1, 2018
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trialVladimir Skljarevski, Manjit Matharu, Brian A Millen, et al.
Headache|November 12, 2019
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE StudiesHolland C Detke, Brian A Millen, Qi Zhang, et al.
BMC Psychiatry|May 23, 2013
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophreniaDavid H Adams, Bruce J Kinon, Simin Baygani, et al.
Schizophrenia Research|September 17, 2013
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placeboVirginia L Stauffer, Brian A Millen, Scott Andersen, et al.
Journal of Clinical Psychopharmacology|April 22, 2011
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophreniaBruce J Kinon, Lu Zhang, Brian A Millen, et al.
Journal of Personalized Medicine|February 11, 2016
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with SchizophreniaLaura K Nisenbaum, AnnCatherine M Downing, Fangyi Zhao, et al.
BMC Psychiatry|December 26, 2014
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaAnnCatherine M Downing, Bruce J Kinon, Brian A Millen, et al.
The New England Journal of Medicine|July 11, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster HeadachePeter J Goadsby, David W Dodick, Massimo Leone, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cephalalgia : an International Journal of Headache|June 1, 2018
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trialVladimir Skljarevski, Manjit Matharu, Brian A Millen, et al.
Headache|November 12, 2019
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE StudiesHolland C Detke, Brian A Millen, Qi Zhang, et al.
BMC Psychiatry|May 23, 2013
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophreniaDavid H Adams, Bruce J Kinon, Simin Baygani, et al.
Schizophrenia Research|September 17, 2013
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placeboVirginia L Stauffer, Brian A Millen, Scott Andersen, et al.
Journal of Clinical Psychopharmacology|April 22, 2011
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophreniaBruce J Kinon, Lu Zhang, Brian A Millen, et al.
Journal of Personalized Medicine|February 11, 2016
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with SchizophreniaLaura K Nisenbaum, AnnCatherine M Downing, Fangyi Zhao, et al.
BMC Psychiatry|December 26, 2014
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaAnnCatherine M Downing, Bruce J Kinon, Brian A Millen, et al.
The New England Journal of Medicine|July 11, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster HeadachePeter J Goadsby, David W Dodick, Massimo Leone, et al.
Pageof 2